story of the week
Comparison of Adjuvant Gemcitabine and Capecitabine With Gemcitabine Monotherapy for Resected Pancreatic Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Comparison of Adjuvant Gemcitabine and Capecitabine With Gemcitabine Monotherapy in Patients With Resected Pancreatic Cancer (ESPAC-4): A Multicentre, Open-Label, Randomised, Phase 3 Trial
Lancet 2017 Jan 24;[EPub Ahead of Print], JP Neoptolemos, DH Palmer, P Ghaneh, EE Psarelli, JW Valle, CM Halloran, O Faluyi, DA O'Reilly, D Cunningham, J Wadsley, S Darby, T Meyer, R Gillmore, A Anthoney, P Lind, B Glimelius, S Falk, JR Izbicki, GW Middleton, S Cummins, PJ Ross, H Wasan, A McDonald, T Crosby, YT Ma, K Patel, D Sherriff, R Soomal, D Borg, S Sothi, P Hammel, T Hackert, R Jackson, MW BüchlerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.